Intranasal Covid vaccine candidate in early clinical stage of development
We Care...!!!

NEW DELHI: An intranasal vaccine candidate (BBV154), being developed by Bharat Biotech, is in early medical stage of growth in India, minister of state for well being Ashwini Choubey instructed the Rajya Sabha on Tuesday.
Choubey was responding to a query on the standing of launching a nasal vaccine for Covid-19.
Most vaccines are administered by injection by intramuscular or subcutaneous route. But, intranasal vaccines are administered as a nasal spray and supply a needle-free method for vaccine administration, Choubey stated in a written reply.
“The interval interval between the 2 doses is presently 21 days. The schedule will probably be finalized after the phase I medical trial information. Currently, in part I medical trial, single dose and two dose schedules are being examined,” the minister stated.


Leave a Reply

Your email address will not be published. Required fields are marked *

Translate »